Chairpersons :

Tejinder Singh, Anand Pathak, S. Karandikar

Reviewer :

Shona Nag

1. Genomic evolution of breast cancer metastasis and relapse

Author: Lucy R. Yates

Citation: Cancer Cell. 2017 Aug 14; 32(2): 169–184.e7.

2. Recurrent and functional regulatory mutations in breast cancer

Author: Esther Rheinbay

Citation: Nature. 2017 Jul 6;547(7661):55-60

3. Association analysis identifies 65 new breast cancer risk loci

Author: Michailidou K.

Citation: Nature. 2017 Nov 2;551(7678):92-94

4. Identification of ten variants associated with risk of Estrogen-Receptor-Negative breast

cancer

Author: Milne RL

Citation: Nat Genet. 2017 Dec;49(12):1767-1778

5. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals

alterations associated with endocrine resistance

Author: JM Giltnane

Citation: Sci Transl Med. 2017 Aug 9;9(402)

6. HR detect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

Author: Helen Davies

Citation: Nat Med. 2017 Apr;23(4):517-525

7. Whole genome sequencing reveals breast cancers with mismatch repair deficiency

Author: Helen Davies

Citation: Cancer Res. 2017 Sep 15;77(18):4755-4762

8. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline

regimens in women with ERBB2/HER2-negative breast cancer the Evaluating Treatment

with Neoadjuvant Abraxane (ETNA) trial. A randomized phase 3 clinical trial

Author: L Gianni

Citation: JAMA Oncol. 2018 Jan 11

9. The global burden of women’s cancers: A grand challenge in global health

Author: Ginsburg O.

Citation: Lancet. 2017 Feb 25;389(10071):847-860

10. Genetic testing and counseling among patients with newly diagnosed breast cancer

Author: Allison W. Kurian

Citation: JAMA. 2017 Feb 7;317(5):531-534

11. Risks of breast, ovarian and contralateral breast cancer for BRCA1 and BRCA2 mutation

carriers

Author: Kuchenbaecker KB

Citation: JAMA. 2017 Jun 20;317(23):2402-2416

12. Active surveillance for low-risk cancers -A viable solution to over treatment?

Author: Megan R. Haymart

Citation: N Engl J Med. 2017 Jul 20;377(3):203-206

13. Are small breast cancers good because they are small or small because they are good?

Author: Donald R. Lannin

Citation: N Engl J Med. 2017 Jun 8;376(23):2286-91

14. Evolution of overall survival according to year of diagnosis (2008-2014) and subtypes,

among 16703 Metastatic Breast Cancer (MBC) patients included in the real life "ESME"

cohort

Author: Suzette Delaloge

Citation: Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 1078-1078

15. An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA):

results in germline BRCA-mutated (gBRCAm) HER2-negative Metastatic Breast Cancer

(MBC)

Author: Domchek SM

Citation: SABCS PD6-11

16. Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast

cancer

Author: Tiffany Traina

Citation: J Clin Oncol. 2018 Jan 26:JCO2016713495

17. Appropriate margins for breast-conserving surgery in patients with early stage breast

cancer: A meta-analysis

Author: Frank Vicini

Citation: SABCS Abstract GS5-01

18. Risk of arm morbidity after local therapy in young breast cancer survivors

Author: L. S. Dominici

Citation: SABCS Abstract GS5-03

19. A phase III multicentre double blind placebo controlled trial of celecoxib versus palcebo in

primary breast cancer patients (REACT- Randomised Europe An Celecoxib Trial)

Author: R. C. Coombes

Citation: SABCS Abstract GS3-03